Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/21/2013 | 11:03am CEST

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: [email protected]

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

[email protected]

Sheryl Seapy

Pure Communications

[email protected]


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
12:46a MACY : US stock market opens higher
12:46a Minerva Neurosciences Announces Pricing of Public Offering of Common Stock
12:45a ZAHRAA EL MAADI INV & DEV SAE : Maadi submits documents to list capital hike by LE11 m
12:44a GLOBAL SYSTEM INFRASTRUCTURE REVENUE MARKET 2017-2021 : Top Drivers and Forecasts by Technavio
12:43a ENVIRONMENTAL WASTE INTERNATIONAL : Announces 2017 Shareholders' Meeting Results
12:42a ENVIRONMENTAL WASTE INTERNATIONAL : Announces 2017 Shareholders' Meeting Results
12:40a FITBIT : 6 Overnight Oat Recipes with Fresh Flavors to Try
12:40a WOLF MINERALS : Bridge Facility with RCF Increased to GBP40 Million
12:39a Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Pingtan Marine Enterprise Ltd.
12:33a New computer virus spreads from Ukraine to disrupt world business
Latest news
Advertisement
Hot News 
14.83%PRELIOS : Shares in Italy's Prelios gain 10 percent on report of Chinese bid
-6.19%Stagecoach shares hit seven-year low after East Coast rail charge
-8.73%PETRA DIAMONDS' : stock tumbles on lower output outlook
-4.90%TBC BANK : Societe Generale Sells Entire Stake
6.41%INSURANCE AUSTRALIA : Anticipates Higher Reserve Release
Most Read News
06:06p WARREN BUFFETT : Buffett's Berkshire on verge of becoming BofA's top shareholder
06:07p DAVID HENRY : Citigroup boosts buybacks, dividends beyond Wall St. expectations
06:24p GLOBAL ROTATING EQUIPMENT MARKET FOR THE OIL AND GAS INDUSTRY PROJECTED TO REACH USD 50.18 BILLION BY 2021 : Technavio
06:33p New computer virus spreads from Ukraine to disrupt world business
06:08p WALT DISNEY : ABC TV settles with beef product maker in 'pink slime' defamation case
Most recommended articles
06/23ECONOMY : The Federal Reserve: Dismal Failure or Shrewd Complicity?
06:33p New computer virus spreads from Ukraine to disrupt world business
06:28p ALPHABET : Uber says never told self-driving car executive to take Waymo files
06:17p Apple's iPhone turns 10, bumpy start forgotten
06:14p WALT DISNEY : ABC TV settles with beef product maker in 'pink slime' defamation case